EFG Asset Management (Americas)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,774
| Closed | -$245K | – | 131 |
|
|
2024
Q1 | $245K | Sell |
1,774
-1,033
| -37% | -$142K | 0.07% | 120 |
|
|
2023
Q4 | $370K | Sell |
2,807
-410
| -13% | -$54K | 0.08% | 117 |
|
|
2023
Q3 | $362K | Buy |
3,217
+77
| +2% | +$8.66K | 0.09% | 117 |
|
|
2023
Q2 | $296K | Buy |
3,140
+469
| +18% | +$44.2K | 0.07% | 126 |
|
|
2023
Q1 | $270K | Buy |
2,671
+603
| +29% | +$61K | 0.06% | 124 |
|
|
2022
Q4 | $247K | Sell |
2,068
-124
| -6% | -$14.8K | 0.06% | 121 |
|
|
2022
Q3 | $233K | Hold |
2,192
| – | – | 0.06% | 127 |
|
|
2022
Q2 | $214K | Sell |
2,192
-130
| -6% | -$12.7K | 0.05% | 127 |
|
|
2022
Q1 | $218K | Buy |
+2,322
| New | +$218K | 0.04% | 132 |
|
|
2020
Q2 | – | Sell |
-20,240
| Closed | -$1.75M | – | 128 |
|
|
2020
Q1 | $1.75M | Buy |
20,240
+229
| +1% | +$19.8K | 0.56% | 63 |
|
|
2019
Q4 | $2.15M | Sell |
20,011
-4,440
| -18% | -$477K | 0.57% | 66 |
|
|
2019
Q3 | $2.2M | Buy |
+24,451
| New | +$2.2M | 0.66% | 61 |
|
|
2019
Q1 | – | Sell |
-22,184
| Closed | -$1.58M | – | 119 |
|
|
2018
Q4 | $1.58M | Buy |
22,184
+2,363
| +12% | +$169K | 0.57% | 65 |
|
|
2018
Q3 | $2.44M | Buy |
+19,821
| New | +$2.44M | 0.7% | 57 |
|